Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
CSE: ALEN.U — AI Meets Digital Health (click to learn more) What’s Behind Cannabis Stock HERB? (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Cadrenal Therapeutics Inc CVKD

Healthcare Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CVKD)

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

GlobeNewswire January 12, 2026

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

ACCESS Newswire December 30, 2025

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

ACCESS Newswire December 29, 2025

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

GlobeNewswire December 17, 2025

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

ACCESS Newswire December 12, 2025

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

ACCESS Newswire December 12, 2025

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire December 11, 2025

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

GlobeNewswire December 1, 2025

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

GlobeNewswire November 19, 2025
View More News ››

Opinion & Analysis (NDAQ:CVKD)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CVKD)

$CVKD $13.8796 +3.73% in the news -Cadrenal Therapeutics

$CVKD $13.8796 +3.73% in the news as Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update...
MasterJediJazz2 - May 13, 2025

CVKD.....My take ....FWIW

This up-coming meeting with FDA could prov to be a major catalyst Caution is needed This has to hold ~ $9.20 or I will say somebody...
Iseneschal - September 13, 2024

CVKD....LoL my timing is impeccable....R u watching the dip?

now at $10.05 and Green to Red move Cheers !
Iseneschal - September 13, 2024

CVKD,,,,$12.00 Holla !!!!

Low volume runner.....I'm out ; ) Sold to America
Iseneschal - September 13, 2024

CVKD......I call this daily action "Walkin the Dog"

Now over $11 which is the highest price since the recent Reverse Split....just sayin Up coming meeting with FDA
Iseneschal - September 13, 2024

Type B FDA Meeting....FYI

What are Type B FDA meetings?     ...
Iseneschal - August 22, 2024
View more Bullboard ››

Electrum Discovery Corp.

Electrum Discovery Corp.

Electrum Discovery Corp. engages in the acquisition and exploration of mineral properties in the natural resource sector in ...
View More »

Podcasts